Oncology Featured Articles
-
Companies To Watch: Soligenix
7/1/2013
Strong federal support and a unique model centered on biodefense therapeutics and vaccines drive this company — and our interest in it.
-
4 Questions For An Oncology Big Pharma CSO
5/30/2013
4 questions about oncology for Dr. Joe Bolen, CSO at Millennium, who has extensive research and management experience within the life sciences industry particularly oncology R&D.
-
Toxicometabolomics For Compound Attrition To Reduce Late Stage Failures Due To Safety
4/10/2013
Many ’omics’ technologies have now become the primary way of discovering new biomarkers, and validation of these biomarkers is a relatively new and evolving concept. By Michael V. Milburn, John A. Ryals, and Lining Guo
-
Growing To Meet The Needs Of Big Pharma: Acquisitions Help BioClinica Increase Profits by 20%
3/26/2013
Recent acquisitions have convinced Mark Weinstein, CEO of BioClinica, that his company is ready to work with the largest of pharmaceutical companies, be they CRO or drug sponsor. Bio-Imaging, which officially became BioClinica in 2009 following a major merger, is currently running over 400 imaging studies with over 200 clients. Weinstein notes a series of well-planned steps were required to get them to this position.
-
Customer Trends In Outsourcing Clinical Research
3/1/2013
The practice of using CROs to conduct clinical trials continues to grow, with clinical research leading the way.
-
ADC: The Next Big Opportunity For Oncology Drugs
2/27/2013
The commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine.
-
Defining A Partnership Strategy For Personalized Medicine
12/28/2012
Personalized medicine is still in its infancy and is expected to drive new levels of partnership activity across the life sciences spectrum, such as: molecular profiling, outcomes data mining, healthcare IT, and data integration.
-
How Shire Leverages Mobile Health Apps For Patient Recruitment
11/29/2012
In an effort to bring patient awareness to available clinical trials, Shire, a biopharmaceutical company, uses mobile health to reach potential patients.
-
The Rx For Dx Leadership At Roche
10/31/2012
Dr. James Creeden, chief medical officer of Roche Professional Diagnostics, shares the strategizing and decision making inside RPD, as well as, the outside world with its competitive landscape and drug-diagnostic combinations.
-
Quantifying The Potential Value Of Orphan Drugs
10/31/2012
An explosive growth to orphan drugs has launched due to government incentives, longer exclusivity rights, and advantageous pricing structures and analysts suggest the CAGR of orphan drugs will outperform non-orphan drugs due to several factors.